VivoSeq
Other

Oxytocin

0

Pipeline Programs

15

Active Trials

2

Companies Involved

Oxytocin is an early-stage landscape with 0 programs across 2 companies. The most active players are Ferring, GSK.

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

9/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

161

clinical trials

Completed108 · 67%
Unknown status22 · 14%
Recruiting13 · 8%
Withdrawn8 · 5%
Terminated7 · 4%
Not yet recruiting2 · 1%
Other1 · 1%

Trial Activity

161 trials

Identifying Oxytocin Deficiency in Adults With Pituitary Disease
Recruiting··Phase 1·NCT06460948·32 enrolled
Oxytocin/Foley vs. Oxytocin for Induction in Patients With PPROM
Recruiting··Phase 4·NCT07119398·80 enrolled
Oxytocin and Fetal Heart Rate Changes
Recruiting··Phase 4·NCT03232918·730 enrolled
Dog Presence and Oxytocin on Trust Towards Therapists
Recruiting··Phase 2/3·NCT06248710·176 enrolled
Oxytocin in Multiparous Women
Not yet recruiting·RRambam Health Care Campus·N/A·NCT06372522·166 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)